How We Help

Donated to NET cancer research
Annual visitors to online resources
Annual patient email and phone inquiries
Patient & caregiver education sessions

NET Cancer is the FASTEST growing class of CANCER worldwide


Neuroendocrine Tumours (NETs) Overview

  • Neuroendocrine tumours (NETs) are abnormal growth of cells (neoplasms) that arise from cells of the diffuse neuroendocrine system.
  • NETs are considered complex tumours because both tumor growth and hormonal function must be addressed.
  • NETs are most common in the lung or gastrointestinal system, but they can also originate in other parts of the body such as the thyroid, thymus, pancreas, adrenals, paraganglia, ovaries and testes.
  • NETs are classified as functional (produce hormones that cause symptoms), or non-functional (may or may not produce hormones and do not cause hormonal symptoms).
  • The cause of NETs is currently unknown.

Contact Us For Live Support

Support Lines:


Toll Free: 1-844-628-6788

Latest CNETS Canada News

ODB lists Afinitor (everolimus) for NETs of Gastrointestinal or Lung origin

November 24th, 2017|0 Comments

We are pleased to announce that Ontario Drug Benefit (ODB) has listed Afinitor (everolimus) for the treatment of patients with GI/Lung NET, effective November 20, 2017 through the Exceptional Access Program (EAP) with the following [...]

World NET Cancer Day a Success in Canada

November 14th, 2017|0 Comments

On Friday, November 10th, 2017 – World NET Cancer Day, businesses and coffee shops around the world raised awareness about NETs using special coffee cups designed for the day. CNETS Canada's partner locations and volunteers [...]

Diagnostic Scan – Ga68

October 4th, 2017|0 Comments

The Gallium 68 scan, used with functional PET imaging, is a nuclear medicine scan that relies on the over-expression of somatostatin receptors to visualize tumours. NETs typically express several somatostatin receptor subtypes in a unique pattern based on [...]

Somatuline (lanreotide) Access in Manitoba & Alberta

October 2nd, 2017|0 Comments

As we advised previously, in July of this year the Manitoba government issued a bulletin…/bulletins/bulletin93.pdf that indicated a change in the listing for Somatuline (from 1 to 3 and no access for NET patients in Manitoba). [...]

Caprelsa (vandetanib) for Medullary Thyroid NETs

October 2nd, 2017|0 Comments

Caprelsa is indicated for the treatment of symptomatic or progressive medullary thyroid cancer (MTC) in adult patients with unresectable locally advanced or metastatic disease.   An application for this drug was put forward to pCODR earlier [...]

Afinitor (everolimus) for NETs of Gastrointestinal or Lung origin

October 2nd, 2017|0 Comments

Afinitor is currently paid for by provincial drug plans for patients with well-or moderately differentiated neuroendocrine tumours of pancreatic origin (pNET), in patients with unresectable, locally advanced or metastatic disease. In 2016 an application was [...]

Donate to CNETS Canada